Why the study?
Extended anticoagulant therapy beyond 6 months is suggested in cancer-associated thrombosis with active cancer, but few data are available on management and outcomes between 6 and 12 months.
In patients with cancer-associated thrombosis surviving the initial 6 months of tinzaparin therapy, extended anticoagulation is common and associated with a 5.7% rate of VTE recurrence and 2.7% rate of major bleeding up to 12 months.
Extended anticoagulation beyond 6 months was associated with low recurrence and bleeding in cancer VTE; leaves open optimal duration in RCTs.
BACKGROUND: extended anticoagulant therapy beyond the initial 6 months is suggested in patients with cancer-associated thrombosis (CAT) and active cancer. Few data are available on patient management and outcomes on the period between 6 and 12 months after the venous thromboembolism (VTE) event. OBJECTIVES: our objective was to document patient management and outcomes beyond 6 months and up to 12 months in CAT patients initially treated for 6 months with tinzaparin. METHODS: adult CAT patients with a cancer still alive at the end of an initial 6-month treatment period were eligible to participate in this retrospective non-interventional French multicenter study. RESULTS: a total of 432 patients aged 66.5 ± 12.7 years were available to participate in this study. Out of the patients included in the study, the anticoagulant treatment was maintained in 348 of 422 documented patients (82.5%) while it was discontinued in 74 (17.5%) patients (before the end or at the end of the initial 6-month treatment period). Between 6 and 12 months, 24 patients (5.7%) experienced VTE recurrence, while 21 (5.1%) patients had clinically relevant bleeding, 11 patients (2.7%) had major bleeding and 96 patients (22.3%) died, mostly from cancer. VTE recurrence was more frequent in patients with lung (14.3%) and colorectal cancer (6.0%) while major bleeding was more frequent in patients with colorectal cancer (6.0%). CONCLUSION: clinical outcomes were consistent with previous observations and variable according to the type of cancer. Further clinical research is required to orient the management of patients with CAT beyond 6 months based on cancer-specific treatment strategies.
No takes yet. Share an insight, caveat, or question.
Mahé et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: